Lovastatin: a new weapon against plague?

Jun 04, 2010
Yersinia pestis after Gram staining. © URMITE/ CNRS

An experimental study has revealed that lovastatin, a drug prescribed for the treatment of hypercholesterolemia, protects animals against the deadly effects of plague. This infectious disease is on the upsurge in parts of the world. These results obtained by French scientists at the Unite de Recherche have been published in the journal PLoS ONE.

Statins are a class of medicinal products administered to reduce cholesterol levels in people at risk of suffering because of their hypercholesterolemia. Of the six compounds available, was the first to be introduced onto the market. Although studies have already demonstrated that this drug can prevent the mortality and morbidity associated with severe infections, no results concerning the that causes fatal plague, called Yersinia pestis, had been available until now.

After inoculating small rodents with the Yersinia pestis bacterium, the team led by Didier Raoult and Michel Drancourt showed that animals treated with lovastatin presented fewer and less severe infections. Lovastatin therefore has preventive properties against plague mortality in an animal model. This experimental study also reveals that this statin has no direct antibiotic effect against Yersinia pestis but that it prevents the development of septicemia.

These findings suggest that people receiving statin-based treatment to reduce their cholesterol levels may be protected against the deadly effects of plague. The cause of severe epidemics over the last two thousand years, plague is now considered as a resurgent disease throughout the world. Nearly 50% of cases worldwide are reported in Madagascar, but is present in Africa (Democratic Republic of Congo, Malawi and Tanzania), Asia (Vietnam) and America, while a few very limited outbreaks have been observed in Europe on the shores of the Caspian Sea.

Explore further: Nervous system may play bigger role in infections than previously known

More information: Saravanan Ayyadurai, Hubert Lepidi, Claude Nappez, Didier Raoult, Michel Drancourt, Lovastatin protects against experimental plague in Mice, PLoS ONE, June 2, 2010.

add to favorites email to friend print save as pdf

Related Stories

Mimic molecules to protect against plague

Jul 04, 2008

Bacteria that cause pneumonic plague can evade our first-line defences, making it difficult for the body to fight infection. In fact, a signature of the plague is the lack of an inflammatory response. Now, scientists have ...

Missing lab mice infected with plague

Sep 15, 2005

The FBI and New Jersey officials have started a hushed but intensive search for three missing lab mice reportedly infected with deadly strains of plague.

Researchers Uncover a Secret of the Black Death

Sep 18, 2006

Yersinia pestis, the bacteria that causes plague, is a sneaky little intruder with a remarkable ability to evade the body’s immune system. Upon entering an organism, Y. pestis employs a variety of strategies to slip below ...

New research shows neuroprotective effect of lovastatin

Apr 09, 2008

High cholesterol levels are considered to be a risk factor for cardiovascular disease including stroke. Therefore, many cholesterol lowering drugs have been developed by pharmaceutical companies in recent years. One class ...

Recommended for you

Stroke damage mechanism identified

3 hours ago

Researchers have discovered a mechanism linked to the brain damage often suffered by stroke victims—and are now searching for drugs to block it.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

CarolinaScotsman
not rated yet Jun 04, 2010
Is the same effect inherrent in all statins? As an aside, many people are surprised to learn that the plague virus is endemic in rodent populations of the US southwest.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.